Radiation Oncology Grand Rounds Series Evaluation - November 16, 2018

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - 0
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 0

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents.	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 5	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 4	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 3	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 2	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 1	Identify the immunological effects that radiation has, which can be exploited in combination with emerging immunotherapy agents. - 0
Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series.	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 5	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 4	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 3	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 2	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 1	Describe the timing of radiation and immune-checkpoint inhibitors are important in improving outcomes in patients, as established in early preclinical models and some early patient outcome series. - 0

Rate the following *

Scoring Key: 5=Excellent 4=Very Good 3=Good 2=Fair 1=Poor

	5	4	3	2	1
Course content.	Course content. - 5	Course content. - 4	Course content. - 3	Course content. - 2	Course content. - 1
Mohammad K Khan, M.D., Ph.D. FACRO	Mohammad K Khan, M.D., Ph.D. FACRO - 5	Mohammad K Khan, M.D., Ph.D. FACRO - 4	Mohammad K Khan, M.D., Ph.D. FACRO - 3	Mohammad K Khan, M.D., Ph.D. FACRO - 2	Mohammad K Khan, M.D., Ph.D. FACRO - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so. *

List topics related to this lecture that you want to learn more about?

Comments

Name

Stay Informed *

Have you updated your email address lately? Please update your email to ensure you receive all CME communications regarding upcoming live meetings, symposiums and online courses offerings.

Yes

No

If you checked "No,” please click here: *

You are here

Radiation Oncology Grand Rounds Series Evaluation - November 16, 2018